SCHEMBL79428

SCHEMBL79428

O=C(O)C=Cc1ccc2c(c1)OCO2

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.81
CYP1A2 P05177 2/20 0.79
HSD17B10 Q99714 2/20 0.79
ALDH1A1 P00352 4/20 0.68
TRPM8 Q7Z2W7 2/20 0.65
MAOB P27338 3/20 0.64
MAPT P10636 4/20 0.62
RAB9A P51151 3/20 0.62
CYP2D6 P10635 2/20 0.62
NPC1 O15118 2/20 0.62
CYP3A4 P08684 2/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
TRPV1 Q8NER1 1/20 0.62
CYP1A1 P04798 1/20 0.62
CYP1B1 Q16678 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
HPGD P15428 4/20 0.61
POLB P06746 1/20 0.61
HDAC6 Q9UBN7 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL79427 1.00 KDM4E (0.81) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8
SCHEMBL4745286 1.00 KDM4E (0.81) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8
SCHEMBL29644896 1.00 KDM4E (0.81) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8
SCHEMBL7995904 1.00 KDM4E (0.81) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8
SCHEMBL29690600 1.00 KDM4E (0.81) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8
SCHEMBL4745288 1.00 KDM4E (0.81) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8
Hydrochloric Acid SCHEMBL6821836 0.98 KDM4E (0.79) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8
Hydrochloric Acid SCHEMBL27927566 0.98 KDM4E (0.79) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8
Pyrrolidine SCHEMBL28573157 0.91 KDM4E (0.68) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8
SCHEMBL10467644 0.91 CYP1A2 (0.71) KDM4ECYP1A2HSD17B10ALDH1A1TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12593844-B2 Method and compounds to induce plant tolerance against arthropod pests VIB VZW (BE) 2026-04-07 US claimed
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
US-20250213637-A1 KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF KUALITY HERBCEUTICS LLC (US) 2025-07-03 US claimed
US-20250163006-A1 New Coolants, and Preparations Containing Same SYMRISE AG (DE) 2025-05-22 US claimed
WO-2025081932-A1 RETINOL DERIVATIVE OR SALT THEREOF, AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 深圳市护家科技有限公司 2025-04-24 WO claimed
CN-119841755-A Retinol derivative or its salt, and preparation method and application thereof 深圳市护家科技有限公司 2025-04-18 CN claimed
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same SYMRISE AG (DE) 2025-02-27 US claimed
CN-112353791-B Slip-derived therapeutic compounds and methods of use thereof 夸利蒂赫布丘蒂克斯公司 2025-02-25 CN claimed
EP-4469439-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-12-04 EP claimed
EP-4452941-A1 ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-10-30 EP claimed
JP-2002541233-A 2002-12-03 JP claimed
CN-1354740-A Pharmaceutical compounds NICOX SA (FR) 2002-06-19 CN claimed
EP-1192129-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-04-03 EP claimed
EP-1169337-A2 STEROID NITRATES FOR THE TREATMENT OF OXIDATIVE INJURY AND ENDOTHELIAL DYSFUNCTION NICOX S.A. (FR) 2002-01-09 EP claimed
EP-1169294-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-01-09 EP claimed
WO-2000061549-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
WO-2000061604-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
WO-2000061537-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
EP-0954596-A1 ENHANCED PRODUCTION OF TAXANES BY CELL CULTURES OF $i(TAXUS) SPECIES PHYTON, INC. (US) 1999-11-10 EP claimed
WO-1997044476-A1 ENHANCED PRODUCTION OF TAXANES BY CELL CULTURES OF TAXUS SPECIES PHYTON, INC. (US) 1997-11-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12593844-B2 Method and compounds to induce plant tolerance against arthropod pests HPD, PAH, P4HTM KDM4E 329/4885CYP1A2 754/4885HSD17B10 681/4885
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same TAS2R5, TAS2R7, TAS2R8 KDM4E 4202/4885CYP1A2 3463/4885HSD17B10 4026/4885
US-20250213637-A1 KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF KLK5, KLK4, KLK2 KDM4E 90/4885CYP1A2 932/4885HSD17B10 591/4885
US-20250163006-A1 New Coolants, and Preparations Containing Same TTR, TAS2R5, TAS2R50 KDM4E 4049/4885CYP1A2 1923/4885HSD17B10 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.